Innate Pharma SA announced that it has entered into a collaboration agreement with Sanofi (SNYNF,SNY) to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates or "ADC".
Sanofi-Aventis Recherche & Développement, the French R&D affiliate of Sanofi, will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety and has the option to enter into a licencing agreement with Innate Pharma on this technology. Other terms of the agreement are undisclosed.
Innate Pharma's coupling technology uses bacterial transglutaminase (BTG) enzyme. It aims to address the heterogeneity associated with traditional ADC coupling technologies which limits the therapeutic index of antibody conjugates. With Innate Pharma's technology, a single point mutation in the antibody's heavy chain generates either two or four specific enzyme-recognition sites, and linkers have been optimized to couple quantitatively at these positions.
For comments and feedback contact: editorial@rttnews.com
Business News